Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Lancet Oncol. 2016 Dec 5;18(1):42–51. doi: 10.1016/S1470-2045(16)30565-4

Table 1.

Baseline characteristics in patients with small-cell lung cancer

Patients (n=74)
Age (years) 61 (55–69)

Sex
 Female 32 (43%)
 Male 42 (57%)

ECOG performance score
 0 21 (28%)
 1 50 (68%)
 2 3 (4%)

Response to first-line treatment
 Sensitive* 39 (53%)
 Resistant 23 (31%)
 Refractory 7 (9%)
 Not assessable 5 (7%)

Treatment-free interval before second-line treatment (months) 4·1 (1·8–7·9)

Previous lines of treatment
 One 39 (53%)
 Two 35 (47%)

History of CNS metastases 21 (28%)

Previous treatments
 Platinum and etoposide 71 (96%)
 Platinum and other drug 5 (7%)
 Platinum, etoposide, and other drug 7 (9%)
 Topotecan 8 (11%)
 Temozolomide 10 (14%)
 ABT-888 8 (11%)
 Radiation 61 (82%)
 Other 16 (22%)

Tumour DLL3 expression§
 ≥1% 42/48 (88%)
 ≥50% 32/48 (67%)

Data are median (IQR) or number of patients (%). ECOG=Eastern Cooperative Group.

*

Defined as a best response of stable disease or better to first-line treatment, and a treatment-free interval between first-line and second-line treatment of 90 days or longer.

Defined as a best response of stable disease or better to first-line treatment, and a treatment-free interval between first-line and second-line treatment of less than 90 days.

Defined as a best response of progressive disease to first-line treatment.

§

Percentage of tumour cells staining positive for DLL3; calculated only in patients with available archived tumour tissue.

HHS Vulnerability Disclosure